Company / Operating Cash Flow
Aligos Therapeutics, Inc. Operating Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$82.5M
FY2025
5-year range
-$115.7M / -$74.3M
FY2021-FY2025
Trend
-2.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$79M to -$83M over the past 2 years.
Based on SEC 10-K filings.
-$83M in FY2025.
Declined from -$79M to -$83M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 2.2% year-over-year.
- Peak operating cash flow was recorded in FY2020.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$82.5M | -2.2% |
| FY2024 | -$80.7M | -1.7% |
| FY2023 | -$79.4M | +31.4% |
| FY2022 | -$115.7M | -55.7% |
| FY2021 | -$74.3M | -58.8% |
| FY2020 | -$46.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026